Literature DB >> 24048903

New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation.

Cláudia C Oliveira1, Bianca Querido, Marjolein Sluijter, Anne F de Groot, Reno van der Zee, Martijn J W E Rabelink, Rob C Hoeben, Ferry Ossendorp, Sjoerd H van der Burg, Thorbald van Hall.   

Abstract

The signal peptide peptidase (SPP) is an intramembrane cleaving aspartyl protease involved in release of leader peptide remnants from the endoplasmic reticulum membrane, hence its name. We now found a new activity of SPP that mediates liberation of C-terminal peptides. In our search for novel proteolytic enzymes involved in MHC class I (MHC-I) presentation, we found that SPP generates the C-terminal peptide-epitope of a ceramide synthase. The display of this immunogenic peptide-MHC-I complex at the cell surface was independent of conventional processing components like proteasome and peptide transporter TAP. Absence of TAP activity even increased the MHC-I presentation of this Ag. Mutagenesis studies revealed the crucial role of the C-terminal location of the epitope and "helix-breaking" residues in the transmembrane region just upstream of the peptide, indicating that SPP directly liberated the minimal 9-mer peptide. Moreover, silencing of SPP and its family member SPPL2a led to a general reduction of surface peptide-MHC-I complexes, underlining the involvement of these enzymes in Ag processing and presentation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24048903     DOI: 10.4049/jimmunol.1301496

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.

Authors:  Elien M Doorduijn; Marjolein Sluijter; Bianca J Querido; Cláudia C Oliveira; Adnane Achour; Ferry Ossendorp; Sjoerd H van der Burg; Thorbald van Hall
Journal:  J Clin Invest       Date:  2016-01-19       Impact factor: 14.808

Review 2.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

3.  Embedded in the Membrane: How Lipids Confer Activity and Specificity to Intramembrane Proteases.

Authors:  Sandra Paschkowsky; Felix Oestereich; Lisa Marie Munter
Journal:  J Membr Biol       Date:  2017-12-19       Impact factor: 1.843

Review 4.  Antigen presentation by MHC-E: a putative target for vaccination?

Authors:  Linda Voogd; Paula Ruibal; Tom H M Ottenhoff; Simone A Joosten
Journal:  Trends Immunol       Date:  2022-03-31       Impact factor: 19.709

Review 5.  Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome.

Authors:  Cláudia C Oliveira; Thorbald van Hall
Journal:  Front Immunol       Date:  2015-06-05       Impact factor: 7.561

6.  Bunyamwera orthobunyavirus glycoprotein precursor is processed by cellular signal peptidase and signal peptide peptidase.

Authors:  Xiaohong Shi; Catherine H Botting; Ping Li; Mark Niglas; Benjamin Brennan; Sally L Shirran; Agnieszka M Szemiel; Richard M Elliott
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-20       Impact factor: 11.205

7.  Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors.

Authors:  Greta Garrido; Brett Schrand; Agata Levay; Ailem Rabasa; Anthony Ferrantella; Diane M Da Silva; Francesca D'Eramo; Koen A Marijt; Zhuoran Zhang; Deukwoo Kwon; Marcin Kortylewski; W Martin Kast; Vikas Dudeja; Thorbald van Hall; Eli Gilboa
Journal:  Cancer Immunol Res       Date:  2020-04-15       Impact factor: 11.151

Review 8.  The nonclassical immune surveillance for ERAAP function.

Authors:  Jian Guan; Josiah David Peske; Joshua A Taylor; Nilabh Shastri
Journal:  Curr Opin Immunol       Date:  2021-06-05       Impact factor: 7.268

9.  Modular transcriptional repertoire and MicroRNA target analyses characterize genomic dysregulation in the thymus of Down syndrome infants.

Authors:  Carlos Alberto Moreira-Filho; Silvia Yumi Bando; Fernanda Bernardi Bertonha; Filipi Nascimento Silva; Luciano da Fontoura Costa; Leandro Rodrigues Ferreira; Glaucio Furlanetto; Paulo Chacur; Maria Claudia Nogueira Zerbini; Magda Carneiro-Sampaio
Journal:  Oncotarget       Date:  2016-02-16

Review 10.  The urgent need to recover MHC class I in cancers for effective immunotherapy.

Authors:  Federico Garrido; Natalia Aptsiauri; Elien M Doorduijn; Angel M Garcia Lora; Thorbald van Hall
Journal:  Curr Opin Immunol       Date:  2016-01-18       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.